Clinical significance of autoantibody expression in allogeneic stem-cell recipients

Transplantation

Volumn 88, Issue 2, 2009, Pages 242-250

  Moon, Joon Ho ^a   Lee, Soo Jung ^a   Kim, Jong Gwang ^a   Chae, Yee Soo ^a   Kim, Shi Nae ^a   Kang, Byung Woog ^a   Suh, Jang Soo ^a   Lee, Kun Soo ^a   Sohn, Sang Kyun ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Allogeneic stem cell transplantation; Autoantibody; Graft versus host disease

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; FLUCONAZOLE; METHOTREXATE; METRONIDAZOLE; PREDNISONE; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DETECTION; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COOMBS TEST; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 68249128209     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ac6885     Document Type: Article

References (38)

1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol 2006; 13: 426.
2. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196.
3. Perreault C, Decary F, Brochu S, et al. Minor histocompatibility antigens. Blood 1990; 76: 1269.
4. Lister J, Messner H, Keystone E, et al. Autoantibody analysis of patients with graft versus host disease. J Clin Lab Immunol 1987; 24: 19.
5. Rouquette-Gally AM, Boyeldieu D, Prost AC, et al. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988; 46: 238.
6. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006; 34: 389.
7. Wechalekar A, Cranfield T, Sinclair D, et al. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005; 27: 247.
8. Fukushi N, Arase H, Wang B, et al. Thymus: A direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci USA 1990; 87: 6301.
9. Desbarats J, Lapp WS. Thymic selection and thymic major histocompatibility complex class II expression are abnormal in mice undergoing graft-versus-host reactions. J Exp Med 1993; 178: 805.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
11. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
12. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942.
13. Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 337.
14. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710.
15. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993.
16. Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: Incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137: 142.
17. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: High prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990; 6: 93.
18. Miflin G, Russell NH, Franklin I, et al. An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy 2000; 2: 423.
19. Weisdorf D. GVHD - The nuts and bolts. Hematology Am Soc Hematol Educ Program 2007; 2007: 62.
20. Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: Comparison with BuCy2. Bone Marrow Transplant 2007; 40: 541.
21. Wiik AS. Anti-nuclear autoantibodies: Clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005; 34: 260.
22. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526.
23. Lacroix-Desmazes S, Kaveri SV, Mouthon L, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998; 216: 117.
24. Watanabe A, Kodera M, Sugiura K, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004; 50: 892.
25. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007; 20: 349.
26. King C, Ilic A, Koelsch K, et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265.
27. Storek J, Joseph A, Dawson MA, et al. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 2002; 73: 1154.
28. Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217.
29. Walker SA, Riches PG, Wild G, et al. Total and allergen-specific IgE in relation to allergic response pattern following bone marrow transplantation. Clin Exp Immunol 1986; 66: 633.
30. Agosti JM, Sprenger JD, Lum LG, et al. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N Engl J Med 1988; 319: 1623.
31. Hallstrand TS, Sprenger JD, Agosti JM, et al. Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors. Blood 2004; 104: 3086.
32. Perruche S, Kleinclauss F, Tiberghien P, et al. B Cell allogeneic responses after hematopoietic cell transplantation: Is it time to address this issue? Transplantation 2005; 79: S37.
33. Chow DA, Bennet RD. Low natural antibody and low in vivo tumor resistance, in xid-bearing B-cell deficient mice. J Immunol 1989; 142: 3702.
34. Fleming SD, Tsokos GC. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev 2006; 5: 89.
35. Cahalon L, Korem S, Gonen B, et al. Autoantibody-mediated regulation of tumor growth. Ann NY Acad Sci 1992; 651: 393.
36. Witz IP, Yaakubowicz M, Gelernter I, et al. Studies on the level of natural antibodies reactive with various tumor cells during urethane carcinogenesis in BALB/c mice. Immunobiology 1984; 166: 131.
37. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667.
38. Gleicher N, Barad D, Weghofer A. Functional autoantibodies, a new paradigm in autoimmunity? Autoimmun Rev 2007; 7: 42.